Condition: Carcinoma, Renal Cell · Sponsor: Oncorena AB
A phase I/II, open-label, study to determine the safety and preliminary efficacy of orellanine in patients with metastatic clear-cell or papillary renal carcinoma who have failed standard-of-care therapy. All participants must have end-stage kidney disease and be receiving stable chronic hemodialysis.
This description comes directly from the study's public registry record.
Börje Haraldsson, M.D., Ph.D. · +46702679544 · borje.haraldsson@oncorena.com
Always discuss trial participation with your own doctor first.
| Stanford | Palo Alto, California, United States | Recruiting |
| Washington University in St. Louis | St Louis, Missouri, United States | Recruiting |
| University of Texas - MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| START Lisbon - Hospital de Santa Maria Av | Lisbon, Portugal | Recruiting |
| Karolinska University Hospital | Stockholm, Sweden | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05287945